Mumbai, February 10, 2018: Pharma Major Alkem Laboratories has inked an out-licensing deal with Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), for Stempeucel merchandise For gout sign.
The outside licensing deal comprises of upfront payment, royalties and respective regulatory & sales based landmarks payments.
Under this agreement, Alkem will get the exclusive marketing rights for Stempeucel in India for Osteoarthritis with Stempeutics manufacturing and supplying the product to Alkem.
The product is expected to be available in Indian market by 2020 after undergoing the stage 3 Clinical trial in India, which is anticipated to commence in 2018.
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…